3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 1/2
2
Status
Completed
2
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Other solid neoplasm
3
Conditions
Melanoma
106
Carcinoma, Non-Small-Cell Lung
34
Carcinoma, Renal Cell
23
Prostatic Neoplasms
17
Neoplasms
15
Brain Neoplasms
15
Neoplasm Metastasis
14
Lung Neoplasms
12
Breast Neoplasms
11
Uveal Melanoma
10
Pancreatic Neoplasms
10
Sarcoma
9
Small Cell Lung Carcinoma
7
Urinary Bladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Kidney Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Skin Neoplasms
5
Ovarian Neoplasms
5
Histiocytoma, Malignant Fibrous
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Recurrence
4
Neuroendocrine Tumors
4
Mesothelioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
Cisplatin
28
Pemetrexed
22
Gemcitabine
10
Nivolumab
9
Carboplatin
9
pembrolizumab
8
tremelimumab
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Doxorubicin
4
Chemotherapy, Adjuvant
4
Vinorelbine
3
Ipilimumab
3
Bortezomib
3
Bevacizumab
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
sodium thiosulfate
2
sargramostim
2
niraparib
2
nintedanib
2
liposomal doxorubicin
2
lenvatinib
2
defactinib
2
cemiplimab
2
cediranib
2
amatuximab
2
Trabectedin
2
Neoadjuvant Therapy
2
Mitomycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma, Malignant
×
Ipilimumab
×
Clear all
NCT05136677
2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2
Completed
102 enrolled
NCT04300244
2024-02-29
NIPU
Oslo University Hospital
Phase 2
Active not recruiting
118 enrolled
NCT03048474
2021-01-20
INITIATE
The Netherlands Cancer Institute
Phase 2
Completed
36 enrolled